Reader response: MT in anticoagulated patients: Direct oral anticoagulants versus vitamin K antagonists
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
L'Allinec et al.1 identified another potential benefit of direct oral anticoagulants (DOACs) compared with vitamin K antagonists (VKA)—in addition to lower rates of stroke, systemic embolism, and intracranial hemorrhage2—by showing higher rates of successful recanalization among patients who underwent mechanical thrombectomy. As a consequence of better recanalization, 90-day rates of excellent outcome (modified Rankin Scale [mRS] score 0–1) and mortality were significantly better in the DOAC group. However, the primary outcome (mRS 0–2) was not significantly different, and the rates of withdrawal of life-sustaining therapy were not accounted for in mortality outcomes. Although the authors hypothesized that variations in clot substance underlie higher reperfusion rates in DOAC users, as many as 50% of VKA users may have been inadequately anticoagulated (28% had international normalized ratio [INR] 1.7%–2.0% and 24% had no available INR data), potentially leading to harder clots that are more difficult to retrieve. The authors did not mention if more VKA-treated patients were enrolled earlier in the study when endovascular technology was less sophisticated. However, the authors' previous ASTER trial suggested that the differences in the use of stent retrievers and direct aspiration among DOAC- and VKA-treated patients is inconsequential.3 Further study of clot composition and its impact on recanalization among anticoagulated patients is needed to enable more targeted thrombectomy techniques.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2020 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.